Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.39 |
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.38 |
| ▸ | LMNA | P02545 | 2/20 | 0.38 |
| ▸ | KDM4E | B2RXH2 | 1/20 | 0.38 |
| ▸ | ALOX5 | P09917 | 1/20 | 0.38 |
| ▸ | CA12 | O43570 | 1/20 | 0.36 |
| ▸ | CA7 | P43166 | 1/20 | 0.36 |
| ▸ | CA9 | Q16790 | 1/20 | 0.36 |
| ▸ | CA14 | Q9ULX7 | 1/20 | 0.36 |
| ▸ | ESRRB | O95718 | 1/20 | 0.36 |
| ▸ | AKT1 | P31749 | 1/20 | 0.35 |
| ▸ | TSHR | P16473 | 1/20 | 0.34 |
| ▸ | MEN1 | O00255 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23527747 | 0.85 | HTR2A (0.40) | KMT2AALDH1A1LMNAKDM4ETSHR | |
| SCHEMBL5970972 | 0.84 | KMT2A (0.42) | KMT2AALDH1A1LMNATSHRMEN1 | |
| SCHEMBL31647824 | 0.84 | ALDH1A1 (0.43) | KMT2AALDH1A1LMNAMEN1 | |
| SCHEMBL838503 | 0.84 | RECQL (0.42) | KMT2AALDH1A1LMNATSHRMEN1 | |
| SCHEMBL838502 | 0.84 | RECQL (0.42) | KMT2AALDH1A1LMNATSHRMEN1 | |
| SCHEMBL839799 | 0.82 | HTT (0.39) | KMT2AALDH1A1KDM4E | |
| SCHEMBL839798 | 0.82 | HTT (0.39) | KMT2AALDH1A1KDM4E | |
| SCHEMBL1806319 | 0.81 | PIN1 (0.41) | KMT2ALMNAKDM4EMEN1 | |
| SCHEMBL31647650 | 0.80 | ALDH1A1 (0.42) | KMT2AALDH1A1 | |
| SCHEMBL31648128 | 0.79 | TDP1 (0.33) | KMT2AALDH1A1LMNAMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 3 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-8501961-B2 | HIV protease inhibitors and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-8501961-B2 | HIV protease inhibitors and methods for using | PURDUE RESEARCH FOUNDATION (US) | 2013-08-06 | — | — | US | disclosed |
| US-20110118330-A1 | HIV PROTEASE INHIBITORS AND METHODS FOR USING | PURDUE RESEARCH FOUNDATION (US) | 2011-05-19 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110118330-A1 | HIV PROTEASE INHIBITORS AND METHODS FOR USING | SERPINB1, PREP, PEPD | KMT2A 3186/4885ALDH1A1 2939/4885LMNA 1000/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.